文献速递卫生政策与健康促进免疫规划

如何加速向全球所有人群供应疫苗?第二部分:从COVID-19疫情中汲取的初步行业经验与详细技术思考

How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation.
PubMed 文献 · Vaccine · 2022-01-01

本文是疫苗行业关于加速全球疫苗可及性的两篇系列文章的第二部分,基于COVID-19大流行的挑战与经验,提出涵盖工艺验证、可比性、稳定性、批准后变更、放行检测、包装、转基因生物及变异株等技术领域的可行可持续方案,倡导采用科学和风险为基础的方法、全球监管协调、依赖与工作共享及认可流程以及数字化,以简化疫苗生产与分销的监管复杂性和异质性。

要点

  • 技术提案覆盖工艺验证、可比性、稳定性、批准后变更、放行检测、包装、转基因生物及变异株等领域。
  • 提案旨在简化疫苗生产与分销的监管复杂性和异质性。
  • 倡导科学和风险为基础的方法、全球监管协调、依赖与工作共享及认可流程以及数字化。

核心结论

  • 基于COVID-19经验提出的技术提案旨在简化疫苗生产与分销的监管复杂性和异质性。

研究设计与样本

  • 本文为疫苗行业视角的两篇系列文章的第二部分,基于COVID-19大流行的挑战与经验提出技术提案。

主要发现

  • 技术提案覆盖工艺验证、可比性、稳定性、批准后变更、放行检测、包装、转基因生物及变异株等关键领域。
  • 提案倡导采用科学和风险为基础的方法、全球监管协调、依赖与工作共享及认可流程以及数字化。
  • 这些提案适用于已上市的常规病原体疫苗以及新发公共卫生威胁病原体的新疫苗生产。

关键数值与推荐

  • 原文未报告具体数值标准或推荐等级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine discovery and vaccination against preventable diseases are one of most important achievements of the human race. While medical, scientific & technological advancements have kept in pace and found their way into treatment options for a vast majority of diseases, vaccines as a prevention tool in the public health realm are found languishing in the gap between such innovations and their easy availability/accessibility to vulnerable populations. This paradox has been best highlighted during the unprecedented crisis of the COVID-19 pandemic. As part of a two series publication on the vaccine industry's view on how to accelerate the availability of vaccines worldwide, this paper offers a deep dive into detailed proposals to enable this objective. These first-of-its-kind technical proposals gleaned from challenges and learnings from the COVID-19 pandemic are applicable to vaccines that are already on the market for routine pathogens as well as for production of new(er) vaccines for emerging pathogens with a public health threat potential. The technical proposals offer feasible and sustainable solutions in pivotal areas such as process validation, comparability, stability, post-approval changes, release testing, packaging, genetically modified organisms and variants, which are linked to manufacturing and quality control of vaccines. Ultimately these proposals aim to ease high regulatory complexity and heterogeneity surrounding the manufacturing & distribution of vaccines, by advocating the use of (1) Science and Risk based approaches, (2) global regulatory harmonization, (3) use of reliance, work-sharing, and recognition processes and (4) digitalization. Capitalizing & collaborating on such new-world advancements into the science of vaccines will eventually benefit the world by turning vaccines into vaccination, ensuring the health of everyone.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McGoldrick M, Gastineau T, Wilkinson D, et al. How to accelerate the supply of vaccines to all populations worldwide? Part II: Initial industry lessons learned and detailed technical reflections leveraging the COVID-19 situation. Vaccine. 2022. PMID: 35180994. doi:10.1016/j.vaccine.2021.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。